Provided by Tiger Trade Technology Pte. Ltd.

Theravance Biopharma

17.07
+0.04000.23%
Post-market: 17.070.00000.00%16:10 EDT
Volume:560.18K
Turnover:9.55M
Market Cap:884.71M
PE:16.33
High:17.08
Open:17.06
Low:17.03
Close:17.03
52wk High:21.03
52wk Low:13.08
Shares:51.83M
Float Shares:25.86M
Volume Ratio:1.19
T/O Rate:2.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.05
EPS(LYR):2.06
ROE:20.91%
ROA:1.33%
PB:3.05
PE(LYR):8.29

Loading ...

Theravance Biopharma - to be Bought by Zymeworks for $17 Per Share in Cash Plus CVR

THOMSON REUTERS
·
Jun 29

Theravance Biopharma - Shareholders to Receive CVR for 80% of Net Proceeds from Ampreloxetine Monetization

THOMSON REUTERS
·
Jun 29

Zymeworks - Deal Financed by $350 Mln Non-recourse Note, $360 Mln Net Cash, $219 Mln Zymeworks Cash

THOMSON REUTERS
·
Jun 29

Zymeworks - Deal Expected to be Accretive to Earnings and Cash Flow

THOMSON REUTERS
·
Jun 29

Zymeworks - to Retain $2.5 Bln Irish Tax Attributes from Theravance Biopharma

THOMSON REUTERS
·
Jun 29

Zymeworks - Theravance Biopharma Expected to Receive $100 Mln Trelegy Ellipta Milestone in Q1 2027

THOMSON REUTERS
·
Jun 29

Zymeworks Said to Near $929 Million Deal for Theravance - Bloomberg News

Reuters
·
Jun 29

Zymeworks is Discussing Paying $17 Per Share for Theravance- Bloomberg News

THOMSON REUTERS
·
Jun 29

Theravance Biopharma announces leadership changes amid restructuring

TIPRANKS
·
Jun 24

Theravance Biopharma SVP Áine Miller to exit in November amid restructuring

Reuters
·
Jun 24

Theravance Biopharma SVP Rhonda Farnum sells 13,314 common shares for $218,073.89

Reuters
·
Jun 18

Theravance Biopharma Shareholders Back Directors and Governance Plans

TIPRANKS
·
Jun 13

Theravance Biopharma shareholders elect directors at annual meeting

Reuters
·
Jun 13

Theravance Biopharma: Solid 1Q26 Execution, Cost Cuts, and YUPELRI Momentum Drive Buy Rating and Price Target Increase to $19

TIPRANKS
·
May 28

Theravance Biopharma reports Q1 EPS (10c) vs. (17c) last year

TIPRANKS
·
May 08

Theravance Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 07

Ireland's Theravance Biopharma Q1 revenue beats estimates on YUPELRI growth

Reuters
·
May 07

Theravance Biopharma Q1 net loss narrows to $4.93 million; revenue rises 15% to $17.7 million

Reuters
·
May 07

Theravance Biopharma Inc: Restructuring Is Expected to Impact About 50% of the Overall Workforce

THOMSON REUTERS
·
May 07

Theravance Biopharma Inc: Full Run-Rate Cost Savings of About$70 Mln Expected to Fully Materialize in Q3

THOMSON REUTERS
·
May 07